Subin Kim, Seong Hyuk Park, Jiyeon Mun, Soon Won Jung, Won Jai Lee, Dong Won Lee, Kee-Won Lee
Peripheral nerves are vulnerable to trauma, pressure, and surgical injuries, complicating the regeneration process. While the autograft remains the gold standard for recovery, limitations such as tissue availability and donor site morbidities have led to the exploration of the allografts. However, conventional detergent-based decellularization methods in preparing allografts often cause residual toxicity and damage to the extracellular matrix (ECM). To address such challenges, we propose a sodium hydroxide (NaOH)-based decellularization technique that minimizes harmful residues. Our findings demonstrate that this method effectively removes inflammatory materials while preserving the ECM components and structures, and significantly reduces lipid and detergent residues. In vitro studies confirmed that the human nerves processed with the NaOH-based decellularization technique show low cytotoxicity and support elevated cell viability and proliferation. We further compared the performance of NaOH-based decellularized human nerves with that of autografts through an in vivo rabbit sciatic nerve defect model. NaOH-based decellularized nerves showed functional recovery comparable to autografts. Our findings demonstrate structural regeneration through neurofilament and laminin expression, indicating recovery levels similar to those of autografts. This study highlights that decellularized human nerve grafts through the NaOH-based protocol can promote nerve regeneration comparable to autografts, which can offer a safe and effective option for the treatment and reconstruction of peripheral nerve defects.
{"title":"Enhancing peripheral nerve regeneration through NaOH-based decellularization of human nerve tissue","authors":"Subin Kim, Seong Hyuk Park, Jiyeon Mun, Soon Won Jung, Won Jai Lee, Dong Won Lee, Kee-Won Lee","doi":"10.1002/btm2.70072","DOIUrl":"10.1002/btm2.70072","url":null,"abstract":"<p>Peripheral nerves are vulnerable to trauma, pressure, and surgical injuries, complicating the regeneration process. While the autograft remains the gold standard for recovery, limitations such as tissue availability and donor site morbidities have led to the exploration of the allografts. However, conventional detergent-based decellularization methods in preparing allografts often cause residual toxicity and damage to the extracellular matrix (ECM). To address such challenges, we propose a sodium hydroxide (NaOH)-based decellularization technique that minimizes harmful residues. Our findings demonstrate that this method effectively removes inflammatory materials while preserving the ECM components and structures, and significantly reduces lipid and detergent residues. In vitro studies confirmed that the human nerves processed with the NaOH-based decellularization technique show low cytotoxicity and support elevated cell viability and proliferation. We further compared the performance of NaOH-based decellularized human nerves with that of autografts through an in vivo rabbit sciatic nerve defect model. NaOH-based decellularized nerves showed functional recovery comparable to autografts. Our findings demonstrate structural regeneration through neurofilament and laminin expression, indicating recovery levels similar to those of autografts. This study highlights that decellularized human nerve grafts through the NaOH-based protocol can promote nerve regeneration comparable to autografts, which can offer a safe and effective option for the treatment and reconstruction of peripheral nerve defects.</p>","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"10 6","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://aiche.onlinelibrary.wiley.com/doi/epdf/10.1002/btm2.70072","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145072141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Margaux Delafosse, Estelle Regnault, Jasmin Gebauer‐Barrett, Andreas Manz, Baeckkyoung Sung
Recent developments in synthetic three‐dimensional (3D) gel microenvironments for cell culture have enabled the advancement of bioengineered organ‐specific cell niches that resemble the native 3D tissue architecture and mechanics. In particular, the application of 3D cell cultures based on miniaturized hydrogel scaffolds for toxicological analyses is attracting increasing interest because of their facile adaptability to on‐chip systems and potential as novel in vitro screening tools. We summarize the current progress in microgel‐based 3D cells integrated into biochip platforms and their utilization for the in vitro toxicity evaluation of chemicals and drug candidates. We emphasize the development of tissue‐mimicking microgel systems combined with automated gel microarray chips and organ‐on‐a‐chip devices. This review begins with the microscale hydrogel scaffolds that encapsulate mammalian cells and are used for in vitro tissue mimicry purposes. Furthermore, an overview of microgel‐based tissue modeling approaches to toxicity testing and screening is provided, along with their technical advantages in drug discovery and alternatives to animal testing.
{"title":"Cell‐embedded microgels as emerging miniature 3D tissue‐mimics toward biochip‐based toxicity screening","authors":"Margaux Delafosse, Estelle Regnault, Jasmin Gebauer‐Barrett, Andreas Manz, Baeckkyoung Sung","doi":"10.1002/btm2.70061","DOIUrl":"https://doi.org/10.1002/btm2.70061","url":null,"abstract":"Recent developments in synthetic three‐dimensional (3D) gel microenvironments for cell culture have enabled the advancement of bioengineered organ‐specific cell niches that resemble the native 3D tissue architecture and mechanics. In particular, the application of 3D cell cultures based on miniaturized hydrogel scaffolds for toxicological analyses is attracting increasing interest because of their facile adaptability to on‐chip systems and potential as novel in vitro screening tools. We summarize the current progress in microgel‐based 3D cells integrated into biochip platforms and their utilization for the in vitro toxicity evaluation of chemicals and drug candidates. We emphasize the development of tissue‐mimicking microgel systems combined with automated gel microarray chips and organ‐on‐a‐chip devices. This review begins with the microscale hydrogel scaffolds that encapsulate mammalian cells and are used for in vitro tissue mimicry purposes. Furthermore, an overview of microgel‐based tissue modeling approaches to toxicity testing and screening is provided, along with their technical advantages in drug discovery and alternatives to animal testing.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"46 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145035155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pankaj Rohilla, Erkan Azizoglu, Sion Park, Atharva Lele, Mark R. Prausnitz, Saad Bhamla
Electroporation‐mediated delivery offers a promising alternative to carrier‐based nucleic acid delivery methods for vaccination and therapeutic applications. Carrier‐based systems like lipid nanoparticles and viral vectors often suffer from poor in vivo stability, immunogenicity, toxicity, and off‐target effects. To overcome the high cost, bulkiness, lack of portability, and painful administration of traditional electroporators, we developed the RotoPatch family of small, low‐cost, hand‐held piezoelectric electroporators that use microneedle electrodes for intradermal delivery of nucleic acids. Notably, these RotoPatch devices use a single rotary motion to administer multiple electroporation pulses through microneedle electrodes, that localize the electric field to the upper layers of the skin. In animals, RotoPatch facilitated greater intracellular uptake of firefly luciferase‐encoded mRNA in mice and green fluorescent protein‐encoded plasmid DNA in rats, as confirmed by bioluminescence and fluorescence imaging, respectively. RotoPatch produced similar in vivo expression as electroporation using a manually actuated, multi‐pulse piezoelectric electroporator (ePatch) and a battery‐powered, multi‐pulse electroporator (eIgniter). These findings highlight the potential of multi‐pulse piezoelectric microneedle electroporation for intradermal nucleic acid delivery as a platform for gene therapy and vaccination.
{"title":"Low‐cost, handheld, multi‐pulse electroporators for simplified nucleic acid delivery in skin","authors":"Pankaj Rohilla, Erkan Azizoglu, Sion Park, Atharva Lele, Mark R. Prausnitz, Saad Bhamla","doi":"10.1002/btm2.70070","DOIUrl":"https://doi.org/10.1002/btm2.70070","url":null,"abstract":"Electroporation‐mediated delivery offers a promising alternative to carrier‐based nucleic acid delivery methods for vaccination and therapeutic applications. Carrier‐based systems like lipid nanoparticles and viral vectors often suffer from poor in vivo stability, immunogenicity, toxicity, and off‐target effects. To overcome the high cost, bulkiness, lack of portability, and painful administration of traditional electroporators, we developed the RotoPatch family of small, low‐cost, hand‐held piezoelectric electroporators that use microneedle electrodes for intradermal delivery of nucleic acids. Notably, these RotoPatch devices use a single rotary motion to administer multiple electroporation pulses through microneedle electrodes, that localize the electric field to the upper layers of the skin. In animals, RotoPatch facilitated greater intracellular uptake of firefly luciferase‐encoded mRNA in mice and green fluorescent protein‐encoded plasmid DNA in rats, as confirmed by bioluminescence and fluorescence imaging, respectively. RotoPatch produced similar in vivo expression as electroporation using a manually actuated, multi‐pulse piezoelectric electroporator (ePatch) and a battery‐powered, multi‐pulse electroporator (eIgniter). These findings highlight the potential of multi‐pulse piezoelectric microneedle electroporation for intradermal nucleic acid delivery as a platform for gene therapy and vaccination.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"66 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145035156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Greta Bertola, Florinda Coro, Arti Ahluwalia, Carmelo De Maria, Ludovica Cacopardo
Contraceptive methods based on intrauterine devices (IUD) typically result in women being constantly exposed to either hormones or copper ions. Although it is well known that the pH in vaginal fluids increases from around 3.5 to 7 during intercourse, pH-responsive materials have yet to be explored for controlling the local release of contraceptive agents. Here, we describe the design of an open-source smart IUD able to modulate copper ion release on demand thanks to the integration of pH-sensitive biopolymer-based hydrogels. Both anionic and cationic hydrogels with different release strategies were investigated. In anionic gels, an increase in pH promotes an increase in the diffusion coefficient; while in cationic gels, an alkaline environment results in shrinking, exposing part of the copper wire. Computational simulations were used to verify that gel thickness was appropriate for minimal copper ion leaching at low pH and effective dose release at higher pH. A thin gel coating was integrated into a commercial IUD using a custom 3D printed mold. Copper ion release was investigated at different time points in acid and basic solutions. The results show that both anionic and cationic gels can be used to engineer smart and safer IUDs.
{"title":"Engineering a smart intrauterine device based on pH-controlled copper release","authors":"Greta Bertola, Florinda Coro, Arti Ahluwalia, Carmelo De Maria, Ludovica Cacopardo","doi":"10.1002/btm2.70066","DOIUrl":"https://doi.org/10.1002/btm2.70066","url":null,"abstract":"<p>Contraceptive methods based on intrauterine devices (IUD) typically result in women being constantly exposed to either hormones or copper ions. Although it is well known that the pH in vaginal fluids increases from around 3.5 to 7 during intercourse, pH-responsive materials have yet to be explored for controlling the local release of contraceptive agents. Here, we describe the design of an open-source smart IUD able to modulate copper ion release on demand thanks to the integration of pH-sensitive biopolymer-based hydrogels. Both anionic and cationic hydrogels with different release strategies were investigated. In anionic gels, an increase in pH promotes an increase in the diffusion coefficient; while in cationic gels, an alkaline environment results in shrinking, exposing part of the copper wire. Computational simulations were used to verify that gel thickness was appropriate for minimal copper ion leaching at low pH and effective dose release at higher pH. A thin gel coating was integrated into a commercial IUD using a custom 3D printed mold. Copper ion release was investigated at different time points in acid and basic solutions. The results show that both anionic and cationic gels can be used to engineer smart and safer IUDs.</p>","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"10 6","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://aiche.onlinelibrary.wiley.com/doi/epdf/10.1002/btm2.70066","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145529970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Feifei Han, Shih-Mo Yang, Ju Xue, Wanying Xie, Yuanfen Liao, Qi Cheng, Dongmei Zhou, Chuanlu Ren, Yubao Cui
The house dust mite Dermatophagoides pteronyssinus produces major allergens (Der p 1, Der p 2, and Der p 23) that require precise IgE detection for clinical diagnosis. We developed a multiplex digital ELISA using fluorescence-encoded micromagnetic beads (532 nm/638 nm dual-wavelength system) coupled with microfluidics to simultaneously quantify serum IgE against these components, with comprehensive evaluation against the clinical standard UniCAP system. The 532 nm channel measured allergen-specific signals via average brightness increase (ABMB) of enzymatically amplified fluorescence, while 638 nm enabled spectral bead differentiation. Comparative evaluation with UniCAP showed the improved digital ELISA achieved uniform 75.0% sensitivity but variable specificity (42.9%–54.5%) across allergens at the 15.8% ABMB threshold. Sample classification results (Der p 1: 9 positive/6 negative; Der p 2: 7/8; Der p 23: 7/8) demonstrated suboptimal positive predictive values (33.3%–60.0%) versus more favorable negative predictive values (60.0%–85.7%), with likelihood ratios (LR+: 1.31–1.65) and Cohen's κ (0.12–0.25) suggesting limited diagnostic reliability. The automated platform offered 60% reduced sample volume (20 μL vs. 50 μL), multiplex capability, and maintained sensitivity for low-titer samples, representing an efficient screening solution pending specificity enhancement.
屋尘螨产生主要的过敏原(Der p1, Der p2和Der p23),需要精确的IgE检测才能进行临床诊断。我们开发了一种多重数字ELISA,使用荧光编码微磁珠(532 nm/638 nm双波长系统)与微流体结合,同时定量血清IgE对这些成分的影响,并对临床标准UniCAP系统进行综合评估。532 nm通道通过酶扩增荧光的平均亮度增加(ABMB)来测量过敏原特异性信号,而638 nm通道用于光谱珠分化。与UniCAP的比较评估显示,改进的数字ELISA在15.8%的ABMB阈值下,对过敏原的灵敏度达到统一的75.0%,但特异性可变(42.9%-54.5%)。样本分类结果(Der p 1:9阳性/6阴性;Der p 2: 7/8; Der p 23: 7/8)显示,阳性预测值(33.3%-60.0%)低于较有利的阴性预测值(60.0%-85.7%),似然比(LR+: 1.31-1.65)和科恩κ(0.12-0.25)表明诊断可靠性有限。自动化平台可减少60%的样本量(20 μL vs 50 μL),具有多重检测能力,并保持对低滴度样品的敏感性,是一种有效的筛选方案,有待特异性增强。
{"title":"A digital ELISA for multiplexed detection of allergen-specific IgE against Der p 1, Der p 2, and Der p 23","authors":"Feifei Han, Shih-Mo Yang, Ju Xue, Wanying Xie, Yuanfen Liao, Qi Cheng, Dongmei Zhou, Chuanlu Ren, Yubao Cui","doi":"10.1002/btm2.70068","DOIUrl":"10.1002/btm2.70068","url":null,"abstract":"<p>The house dust mite <i>Dermatophagoides pteronyssinus</i> produces major allergens (Der p 1, Der p 2, and Der p 23) that require precise IgE detection for clinical diagnosis. We developed a multiplex digital ELISA using fluorescence-encoded micromagnetic beads (532 nm/638 nm dual-wavelength system) coupled with microfluidics to simultaneously quantify serum IgE against these components, with comprehensive evaluation against the clinical standard UniCAP system. The 532 nm channel measured allergen-specific signals via average brightness increase (ABMB) of enzymatically amplified fluorescence, while 638 nm enabled spectral bead differentiation. Comparative evaluation with UniCAP showed the improved digital ELISA achieved uniform 75.0% sensitivity but variable specificity (42.9%–54.5%) across allergens at the 15.8% ABMB threshold. Sample classification results (Der p 1: 9 positive/6 negative; Der p 2: 7/8; Der p 23: 7/8) demonstrated suboptimal positive predictive values (33.3%–60.0%) versus more favorable negative predictive values (60.0%–85.7%), with likelihood ratios (LR+: 1.31–1.65) and Cohen's <i>κ</i> (0.12–0.25) suggesting limited diagnostic reliability. The automated platform offered 60% reduced sample volume (20 μL vs. 50 μL), multiplex capability, and maintained sensitivity for low-titer samples, representing an efficient screening solution pending specificity enhancement.</p>","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"10 6","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://aiche.onlinelibrary.wiley.com/doi/epdf/10.1002/btm2.70068","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144915610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ulcerative colitis (UC) remains a significant therapeutic challenge due to its complex pathogenesis involving oxidative stress, immune dysregulation, and gut microbiota dysbiosis. Melanin, a natural biopolymer with robust anti-inflammatory and antioxidant properties, presents a promising treatment avenue for UC. Probiotics, particularly Escherichia coli Nissle 1917 (EcN), have gained recognition for their role in restoring gut homeostasis. In this study, we genetically engineered EcN to overexpress tyrosinase (EcN-T), facilitating the biosynthesis of melanin specifically for UC treatment. The engineered probiotics demonstrated superior therapeutic efficacy compared to either melanin or EcN administered alone, highlighting a synergistic effect. EcN-T not only exhibited significant capabilities in scavenging reactive oxygen species and restoring gut microbiota but also possessed the characteristic of enhancing gut colonization time, thereby extending the dosing frequency. Moreover, EcN-T showcased novel mechanisms, such as the restoration of the intestinal mucosal barrier and the elevation of short-chain fatty acid levels. Additionally, EcN-T inhibited M1 macrophage polarization through Hypoxia-Inducible Factor 1-alpha (HIF-1α)dependent glycolytic reprogramming, underscoring its immunomodulatory potential. Collectively, these findings provide new insights into the therapeutic potential of EcN-T for UC treatment, offering a novel strategy that enhances treatment efficacy while potentially reducing side effects associated with conventional therapies.
{"title":"Engineered probiotic alleviates ulcerative colitis by inhibiting M1 macrophage polarization via glycolytic reprogramming","authors":"Chaoqun Lv, Xinyue Hu, Xiang Li, Wen Shi, Wenbo Li, Yan He, Hongqing Li, Jianxi Bai, Zhenxing Li, Zhipeng Wen, Xinxin Liu, Yuanyuan Ai, Jingchao Li, Xiao Chen, Kaijun Liu","doi":"10.1002/btm2.70067","DOIUrl":"10.1002/btm2.70067","url":null,"abstract":"<p>Ulcerative colitis (UC) remains a significant therapeutic challenge due to its complex pathogenesis involving oxidative stress, immune dysregulation, and gut microbiota dysbiosis. Melanin, a natural biopolymer with robust anti-inflammatory and antioxidant properties, presents a promising treatment avenue for UC. Probiotics, particularly <i>Escherichia coli</i> Nissle 1917 (EcN), have gained recognition for their role in restoring gut homeostasis. In this study, we genetically engineered EcN to overexpress tyrosinase (EcN-T), facilitating the biosynthesis of melanin specifically for UC treatment. The engineered probiotics demonstrated superior therapeutic efficacy compared to either melanin or EcN administered alone, highlighting a synergistic effect. EcN-T not only exhibited significant capabilities in scavenging reactive oxygen species and restoring gut microbiota but also possessed the characteristic of enhancing gut colonization time, thereby extending the dosing frequency. Moreover, EcN-T showcased novel mechanisms, such as the restoration of the intestinal mucosal barrier and the elevation of short-chain fatty acid levels. Additionally, EcN-T inhibited M1 macrophage polarization through Hypoxia-Inducible Factor 1-alpha (HIF-1α)dependent glycolytic reprogramming, underscoring its immunomodulatory potential. Collectively, these findings provide new insights into the therapeutic potential of EcN-T for UC treatment, offering a novel strategy that enhances treatment efficacy while potentially reducing side effects associated with conventional therapies.</p>","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"10 6","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://aiche.onlinelibrary.wiley.com/doi/epdf/10.1002/btm2.70067","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144915615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexander Josowitz, Arjun Sree Manoj, Danielle Laiacona, Marc Pelletier, Diana Molano, Samuel Jennings, Cassie Ng, Charlotte Antoni, Grace Chan, Robert Mahoney, Sanket Patel, Ellen‐Marie Koehler‐Stec, Marc Retter, Joel Kantrowitz, Bindhu Rayaprolu, Eric Holowka, Amardeep Singh Bhalla, Mohammed Shameem
The increased preference amongst health care providers and patients for subcutaneous (SC) administration of biologics has necessitated the development of higher concentration formulations to maintain doses similar to intravenous (IV) products. These formulations possess manufacturing and administration challenges; particularly high concentration monoclonal antibody (mAb) formulations push the limit of injectability. Furthermore, patient‐centric considerations, such as pain and fear of needles (trypanophobia), can lead to compliance deviations for long‐term treatments. This study presents a set of evaluations of a novel computer‐controlled, needle‐free injector (NFI) design that can deliver 2.0 mL of a high viscosity (50 cP) mAb formulation into the SC space. Critical attributes such as antibody purity, aggregation, color, turbidity, and charge heterogeneity were evaluated before and after ejection and demonstrated minimal change compared to ejection from a 27‐gauge needle and syringe (N&S). Furthermore, the device functionality was evaluated in a novel ex vivo pig skin model, demonstrating the ability to accurately deposit a 2.0 mL dose at an appropriate depth in the SC tissue, though requiring 8% greater fill volume than an N&S. An in vivo Yorkshire pig model was used to understand the pharmacokinetic (PK) profile of the NFI in comparison to a N&S. Clearance (CL), the observed peak concentration in serum (Cmax), the time until Cmax (Tmax), area under the concentration‐time curve extrapolated to infinity (AUCinf), and half‐life (t1/2) were all within 1.2 fold and considered similar between the NFI and N&S. A non‐significant difference in Tmax was also observed. Bioavailability relative to IV administration was similar between the NFI (80.0%) and N&S (79.5%) groups. No concerning clinical observations and injection site reactions were observed. Ultimately, the NFI represents an advancement in SC delivery of high concentration mAb formulations with patient‐centric design. This device could facilitate clinical and at‐home use while complementing efforts to bridge IV and SC formulations.
{"title":"Feasibility and pharmacokinetic evaluation of a needle‐free injector for delivering high concentration antibody formulations","authors":"Alexander Josowitz, Arjun Sree Manoj, Danielle Laiacona, Marc Pelletier, Diana Molano, Samuel Jennings, Cassie Ng, Charlotte Antoni, Grace Chan, Robert Mahoney, Sanket Patel, Ellen‐Marie Koehler‐Stec, Marc Retter, Joel Kantrowitz, Bindhu Rayaprolu, Eric Holowka, Amardeep Singh Bhalla, Mohammed Shameem","doi":"10.1002/btm2.70063","DOIUrl":"https://doi.org/10.1002/btm2.70063","url":null,"abstract":"The increased preference amongst health care providers and patients for subcutaneous (SC) administration of biologics has necessitated the development of higher concentration formulations to maintain doses similar to intravenous (IV) products. These formulations possess manufacturing and administration challenges; particularly high concentration monoclonal antibody (mAb) formulations push the limit of injectability. Furthermore, patient‐centric considerations, such as pain and fear of needles (trypanophobia), can lead to compliance deviations for long‐term treatments. This study presents a set of evaluations of a novel computer‐controlled, needle‐free injector (NFI) design that can deliver 2.0 mL of a high viscosity (50 cP) mAb formulation into the SC space. Critical attributes such as antibody purity, aggregation, color, turbidity, and charge heterogeneity were evaluated before and after ejection and demonstrated minimal change compared to ejection from a 27‐gauge needle and syringe (N&S). Furthermore, the device functionality was evaluated in a novel ex vivo pig skin model, demonstrating the ability to accurately deposit a 2.0 mL dose at an appropriate depth in the SC tissue, though requiring 8% greater fill volume than an N&S. An in vivo Yorkshire pig model was used to understand the pharmacokinetic (PK) profile of the NFI in comparison to a N&S. Clearance (CL), the observed peak concentration in serum (<jats:italic>C</jats:italic><jats:sub>max</jats:sub>), the time until <jats:italic>C</jats:italic><jats:sub>max</jats:sub> (<jats:italic>T</jats:italic><jats:sub>max</jats:sub>), area under the concentration‐time curve extrapolated to infinity (AUC<jats:sub>inf</jats:sub>), and half‐life (<jats:italic>t</jats:italic><jats:sub>1/2</jats:sub>) were all within 1.2 fold and considered similar between the NFI and N&S. A non‐significant difference in <jats:italic>T</jats:italic><jats:sub>max</jats:sub> was also observed. Bioavailability relative to IV administration was similar between the NFI (80.0%) and N&S (79.5%) groups. No concerning clinical observations and injection site reactions were observed. Ultimately, the NFI represents an advancement in SC delivery of high concentration mAb formulations with patient‐centric design. This device could facilitate clinical and at‐home use while complementing efforts to bridge IV and SC formulations.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"28 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144906049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Neuronal activity underlies the brain function. Different behaviors, physiological processes, and disorders depend on which neurons are active at a given moment. Treating brain disorders without side effects will require exclusive control of disease‐relevant neurons. Traditionally, small molecule drugs could control a subset of neurons that express a molecularly specific receptor. Local noninvasive therapies such as delivery of neuromodulatory agents with focused ultrasound blood–brain barrier opening (FUS‐BBBO) also added spatial precision, allowing one to control specific brain regions without surgery. However, the final characteristic of neurons, which other neurons they connect to, remains underexplored as a therapeutic target. If targeting neurons based on their connectivity was possible noninvasively, it would open the doors to broadly deployable precise therapies that can target selected subgroups of neurons within a brain region. Such delivery could be achieved with retrograde‐tracing adeno‐associated viral vectors (AAVs). For noninvasive delivery with FUS‐BBBO, AAV9 has emerged as the most promising serotype. However, its retrograde‐tracing version, the AAV9.retro, has not been evaluated for FUS‐BBBO delivery. Here, we show that following such noninvasive delivery, AAV9.retro can safely transduce neuronal projections with comparable efficiency to a direct intracranial injection. Compared to AAV8, a naturally occurring vector with low retrograde transduction, AAV9.retro offers superior retrograde transduction and comparable transduction at the site of delivery. Overall, we show that AAV9.retro is a valuable FUS‐BBBO gene delivery vector, while also highlighting the surprising possibility of improved specificity of transduction of projections compared to invasive delivery.
{"title":"Site‐specific noninvasive delivery of retrograde viral vectors to the brain","authors":"Manwal Harb, Shirin Nouraein, Jerzy O. Szablowski","doi":"10.1002/btm2.70062","DOIUrl":"https://doi.org/10.1002/btm2.70062","url":null,"abstract":"Neuronal activity underlies the brain function. Different behaviors, physiological processes, and disorders depend on which neurons are active at a given moment. Treating brain disorders without side effects will require exclusive control of disease‐relevant neurons. Traditionally, small molecule drugs could control a subset of neurons that express a molecularly specific receptor. Local noninvasive therapies such as delivery of neuromodulatory agents with focused ultrasound blood–brain barrier opening (FUS‐BBBO) also added spatial precision, allowing one to control specific brain regions without surgery. However, the final characteristic of neurons, which other neurons they connect to, remains underexplored as a therapeutic target. If targeting neurons based on their connectivity was possible noninvasively, it would open the doors to broadly deployable precise therapies that can target selected subgroups of neurons within a brain region. Such delivery could be achieved with retrograde‐tracing adeno‐associated viral vectors (AAVs). For noninvasive delivery with FUS‐BBBO, AAV9 has emerged as the most promising serotype. However, its retrograde‐tracing version, the AAV9.retro, has not been evaluated for FUS‐BBBO delivery. Here, we show that following such noninvasive delivery, AAV9.retro can safely transduce neuronal projections with comparable efficiency to a direct intracranial injection. Compared to AAV8, a naturally occurring vector with low retrograde transduction, AAV9.retro offers superior retrograde transduction and comparable transduction at the site of delivery. Overall, we show that AAV9.retro is a valuable FUS‐BBBO gene delivery vector, while also highlighting the surprising possibility of improved specificity of transduction of projections compared to invasive delivery.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"13 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144899078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ashis Kumar Podder, Pihu Mehrotra, Pedro Lei, Stelios T. Andreadis
Human skin-derived neural crest (NC)-like stem cells present a highly accessible, autologous source of multipotent cells, with the potential to differentiate into a variety of cell types, including Schwann cells (SCs). However, these cells quickly lose their stem-like characteristics in vitro and eventually limit their ability to form functional SCs. To overcome this, we investigated SOX10 upregulation, the key regulator of NC formation and multipotency, using both small chemical (Forskolin and RepSox) treatment and genetic modification. Remarkably, SOX10 upregulation highly increased SC gene expression instead of NC markers, though Forskolin-RepSox also triggered melanocytic and smooth muscle gene markers alongside reduced NC genes. In contrast, genetic SOX10 upregulation enhanced both SOX10 and NC gene expression without inducing alternative lineages. Continuous SOX10 expression was necessary for increased SC protein markers, and differentiating SOX10-overexpressing cells on immobilized NRG1 further enhanced SC markers and induced a distinct, elongated morphology typical for myelinating SCs. Therefore, this study introduces a rapid, efficient method to derive SC-like cells from the skin-derived NCs, highlighting their potential in regenerative medicine for cell therapy and disease modeling applications.
{"title":"Enhanced Schwann cell differentiation of skin-derived neural crest-like stem cells through the synergistic action of SOX10 and immobilized NRG1 signaling","authors":"Ashis Kumar Podder, Pihu Mehrotra, Pedro Lei, Stelios T. Andreadis","doi":"10.1002/btm2.70041","DOIUrl":"https://doi.org/10.1002/btm2.70041","url":null,"abstract":"<p>Human skin-derived neural crest (NC)-like stem cells present a highly accessible, autologous source of multipotent cells, with the potential to differentiate into a variety of cell types, including Schwann cells (SCs). However, these cells quickly lose their stem-like characteristics in vitro and eventually limit their ability to form functional SCs. To overcome this, we investigated SOX10 upregulation, the key regulator of NC formation and multipotency, using both small chemical (Forskolin and RepSox) treatment and genetic modification. Remarkably, SOX10 upregulation highly increased SC gene expression instead of NC markers, though Forskolin-RepSox also triggered melanocytic and smooth muscle gene markers alongside reduced NC genes. In contrast, genetic SOX10 upregulation enhanced both SOX10 and NC gene expression without inducing alternative lineages. Continuous SOX10 expression was necessary for increased SC protein markers, and differentiating SOX10-overexpressing cells on immobilized NRG1 further enhanced SC markers and induced a distinct, elongated morphology typical for myelinating SCs. Therefore, this study introduces a rapid, efficient method to derive SC-like cells from the skin-derived NCs, highlighting their potential in regenerative medicine for cell therapy and disease modeling applications.</p>","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"10 6","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://aiche.onlinelibrary.wiley.com/doi/epdf/10.1002/btm2.70041","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145529834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wenyu Fu, Ruier Xue, Mohit N. Shivdasani, Yanfang Wu, Dongfei Chen, Tianruo Guo, Nigel H. Lovell, Ewa M. Goldys, Tingxiu Xiang, Yanan Huang, Fei Deng
Inflammatory bowel disease (IBD) encompasses a group of intestinal disorders, primarily Crohn's disease (CD) and ulcerative colitis (UC), characterized by chronic inflammation of the digestive tract. Despite extensive research, the etiology of IBD remains largely unknown, and its progression and prognosis are unpredictable, often involving uncontrolled disease behavior. Current diagnostic and monitoring techniques, such as endoscopy, scoring systems, computed tomography, and ultrasound, provide valuable tools for assessing and monitoring disease progression; but are often used in conjunction with biomarker testing to achieve rapid and accurate results. Recent advances in biosensors, which integrate biorecognition elements with signal transduction platforms, offer immense potential to improve IBD diagnostics by enabling real-time, precise, and non-invasive detection of biomarkers such as C-reactive protein, calprotectin, and cytokines. This review examines existing IBD diagnostic techniques, their limitations, and the emerging role of biosensors in addressing these challenges. It explores the development of electrochemical and optical biosensors, highlights the key biomarkers utilized in these technologies, and identifies challenges and future opportunities for advancing next-generation biosensors for IBD diagnostics and monitoring. These innovations hold promise for enhancing IBD diagnosis, monitoring, and personalized disease management.
{"title":"Advances in biosensors for diagnosis and monitoring of inflammatory bowel disease: A review","authors":"Wenyu Fu, Ruier Xue, Mohit N. Shivdasani, Yanfang Wu, Dongfei Chen, Tianruo Guo, Nigel H. Lovell, Ewa M. Goldys, Tingxiu Xiang, Yanan Huang, Fei Deng","doi":"10.1002/btm2.70064","DOIUrl":"https://doi.org/10.1002/btm2.70064","url":null,"abstract":"<p>Inflammatory bowel disease (IBD) encompasses a group of intestinal disorders, primarily Crohn's disease (CD) and ulcerative colitis (UC), characterized by chronic inflammation of the digestive tract. Despite extensive research, the etiology of IBD remains largely unknown, and its progression and prognosis are unpredictable, often involving uncontrolled disease behavior. Current diagnostic and monitoring techniques, such as endoscopy, scoring systems, computed tomography, and ultrasound, provide valuable tools for assessing and monitoring disease progression; but are often used in conjunction with biomarker testing to achieve rapid and accurate results. Recent advances in biosensors, which integrate biorecognition elements with signal transduction platforms, offer immense potential to improve IBD diagnostics by enabling real-time, precise, and non-invasive detection of biomarkers such as C-reactive protein, calprotectin, and cytokines. This review examines existing IBD diagnostic techniques, their limitations, and the emerging role of biosensors in addressing these challenges. It explores the development of electrochemical and optical biosensors, highlights the key biomarkers utilized in these technologies, and identifies challenges and future opportunities for advancing next-generation biosensors for IBD diagnostics and monitoring. These innovations hold promise for enhancing IBD diagnosis, monitoring, and personalized disease management.</p>","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"10 6","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://aiche.onlinelibrary.wiley.com/doi/epdf/10.1002/btm2.70064","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145522051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}